A clinical trial of donanemab has showed the drug significantly slows cognitive and functional decline in people with early symptomatic disease. It is estimated that almost 400,000 people in Australia had dementia in 2022.
Lecanemab was approved by the US Food and Drug Administration (FDA) as a treatment for early Alzheimer's disease in January 2023. This means that it can now be given to patients with early Alzheimer's disease in the USA.
“Based on today's early results, donanemab appears to slow the progression of Alzheimer's symptoms by 36 % (as compared with 27% of last year's breakthrough drug lecanemab). Promisingly, the trial also demonstrated a 40% slowing in decline of everyday activities such as driving, doing hobbies and managing finances.
Lecanemab is a disease modifying treatment for people living with the early stages of Alzheimer's disease or mild cognitive impairment. The drug includes antibodies which are designed to attach to and remove amyloid plaques.
In the press release, Eli Lilly said that people with mild Alzheimer's who received donanemab showed 35% less clinical decline over 18 months than did those who received a placebo, and 40% less decline in their ability to perform daily tasks.
A medication known as memantine, an N-methyl-D-aspartate (NMDA) antagonist, can be prescribed to treat moderate to severe Alzheimer's. This drug's main effect is to decrease symptoms, which could enable some people to maintain certain daily functions a little longer than they would without the medication.
Cholinisterase Inhibitors are the most commonly prescribed medications for dementia. There are 3 cholinisterase inhibitors, which include, Donepezil, Galantamine and Rivastigmine.
Creutzfeldt-Jakob disease causes a type of dementia that gets worse unusually fast. More common causes of dementia, such as Alzheimer's, dementia with Lewy bodies and frontotemporal dementia, typically progress more slowly.
There is currently no "cure" for dementia. In fact, because dementia is caused by different diseases it is unlikely that there will be a single cure for dementia. Research is aimed at finding cures for dementia-causing diseases, such as Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies.
Many people affected by dementia are concerned that they may inherit or pass on dementia. The majority of dementia is not inherited by children and grandchildren. In rarer types of dementia there may be a strong genetic link, but these are only a tiny proportion of overall cases of dementia.
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease.
Donepezil (also known as Aricept), rivastigmine (Exelon) and galantamine (Reminyl) are used to treat the symptoms of mild to moderate Alzheimer's disease. Donepezil is also used to treat more severe Alzheimer's disease.
Administration: The examiner reads a list of 5 words at a rate of one per second, giving the following instructions: “This is a memory test. I am going to read a list of words that you will have to remember now and later on. Listen carefully. When I am through, tell me as many words as you can remember.
The Mini-Cog test.
A third test, known as the Mini-Cog, takes 2 to 4 minutes to administer and involves asking patients to recall three words after drawing a picture of a clock. If a patient shows no difficulties recalling the words, it is inferred that he or she does not have dementia.
What are the foods that fight memory loss? Berries, fish, and leafy green vegetables are 3 of the best foods that fight memory loss. There's a mountain of evidence showing they support and protect brain health.
Safer Medications to Consider
Alternative prescription medications include ramelteon (Rozerem®), low dose trazodone (Oleptro®, Desyrel®) or low dose mirtazapine (Remeron®).
Examples: Acetazolamide (Diamox), carbamazepine (Tegretol), gabapentin (Neurontin), lamotrigine (Lamictal), levetiracetam (Keppra), oxcarbazepine (Trileptal), pregabalin (Lyrica), rufinamide (Banzel), topiramate (Topamax), valproic acid (Depakote) and zonisamide (Zonegran).
It is recommended that people with Alzheimer's should NOT take anticholinergic drugs. These drugs are used to treat many medical problems such as sleeping problems, stomach cramps, incontinence, asthma, motion sickness, and muscle spasms. Side effects, such as confusion, can be serious for a person with Alzheimer's.
The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease.